prx-13 Antibody

PRX-102 and Anti-Drug Antibodies (ADAs)

PRX-102 (pegunigalsidase alfa) is a PEGylated enzyme replacement therapy (ERT) for Fabry disease. Antibodies against PRX-102 have been studied in clinical trials:

Key Findings:

• PRX-102 demonstrates reduced immunogenicity compared to agalsidase beta, with fewer patients developing neutralizing antibodies over time .

• Pre-existing anti-agalsidase beta antibodies show lower affinity for PRX-102, suggesting structural differences in epitope exposure .

Anti-PRX Antibodies in Research

An anti-PRX polyclonal antibody (Catalog #76464-556) is commercially available for detecting PRX proteins in humans, mice, and rats. Specifications include:

Research Implications:

• Used to study oxidative stress mechanisms and redox signaling .

• No direct clinical data on therapeutic use or ADA formation for this antibody.

Antibody Structure and Function

Antibodies targeting PRX-102 or other PRX-related proteins follow canonical immunoglobulin structures:

• Fab region: Binds to PRX-102’s PEGylated epitopes or peroxiredoxin domains .

• Fc region: Mediates immune effector functions (e.g., complement activation) .

Neutralization Mechanisms:

• Anti-PRX-102 antibodies reduce enzyme activity by blocking substrate binding or accelerating clearance .

• PEGylation of PRX-102 reduces immunogenicity by masking epitopes, though some patients still develop ADAs .

Impact of Anti-PEG Antibodies on PRX-102

SARS-CoV-2 mRNA vaccines have been linked to de novo anti-PEG antibody formation, which cross-react with PRX-102:

Clinical Relevance:

• Anti-PEG antibodies may complicate PRX-102 therapy in vaccinated Fabry patients .

Comparative Analysis of PRX-Targeting Antibodies

Research Gaps and Future Directions

• No studies specifically address "prx-13 Antibody," suggesting either a nomenclature discrepancy or a less-characterized target.

• PRX-102 remains the most studied PRX-associated therapeutic, with ADA profiles well-documented in Phase III trials .